The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
Howard S. Hochster
No relevant relationships to disclose
Wells A. Messersmith
No relevant relationships to disclose
Bert H. O'Neil
No relevant relationships to disclose
Susan G. Groshen
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose
Deirdre Jill Cohen
No relevant relationships to disclose
Crystal Shereen Denlinger
No relevant relationships to disclose
Philip Jordan Gold
No relevant relationships to disclose
S. Gail Eckhardt
No relevant relationships to disclose
Gershon Y. Locker
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Patricia Ames
No relevant relationships to disclose
Marti McKinley
No relevant relationships to disclose
Lawrence P. Leichman
No relevant relationships to disclose